Piper Sandler Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $8.00

Health Catalyst (NASDAQ:HCAT) had its price objective trimmed by Piper Sandler from $12.00 to $8.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other analysts also recently issued reports about the stock. Wells Fargo & Company lowered their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a report on Tuesday, January 21st. Canaccord Genuity Group lowered their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 21st. Royal Bank of Canada lowered their price target on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a report on Wednesday, January 8th. Finally, Stephens increased their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.20.

Health Catalyst Stock Up 2.0 %

HCAT stock opened at $5.55 on Tuesday. The firm’s fifty day simple moving average is $6.64 and its 200-day simple moving average is $7.37. The company has a market capitalization of $337.72 million, a P/E ratio of -4.11 and a beta of 1.34. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a 12 month low of $5.32 and a 12 month high of $10.14.

Insiders Place Their Bets

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total transaction of $67,050.00. Following the completion of the transaction, the insider now directly owns 236,950 shares in the company, valued at approximately $2,118,333. This represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the transaction, the insider now owns 98,702 shares of the company’s stock, valued at $777,771.76. This represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,169 shares of company stock worth $629,068. Company insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds have recently modified their holdings of HCAT. Quantbot Technologies LP acquired a new stake in shares of Health Catalyst in the fourth quarter valued at about $29,000. Quest Partners LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at about $34,000. nVerses Capital LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at about $59,000. Stoneridge Investment Partners LLC acquired a new stake in shares of Health Catalyst in the fourth quarter valued at about $77,000. Finally, Martin Worley Group acquired a new stake in shares of Health Catalyst in the fourth quarter valued at about $78,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.